文献速递慢性肾脏病血液净化与透析

《医疗保险准入与CHIP再授权法案》:对肾脏病学的影响

The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology.
PubMed 文献 · J Am Soc Nephrol · 2017-07-28

本文解读2015年美国通过的《医疗保险准入与CHIP再授权法案》,该法案通过按绩效付费系统改变报销方式,奖励高价值医疗。自2017年初起,提供者将接受质量和成本的评估,高质量低成本者获奖励,低质量高成本者受经济惩罚。CMS将通过开发中的诊疗 episode 和替代支付模型评估成本,当前透析替代支付模型未涵盖CKD向ESRD的过渡。

要点

  • 法案实施按绩效付费,2017年起评估质量,后续年份评估成本。
  • 高质量低成本提供者获报销奖励,低质量高成本者受经济惩罚。
  • 现有透析替代支付模型未覆盖CKD向ESRD过渡阶段。

核心结论

  • 法案通过按绩效付费系统奖励高价值医疗,惩罚低质量高成本医疗,肾脏病提供者需发展成本效益高的护理方式。

研究设计与样本

  • 原文为对2015年《医疗保险准入与CHIP再授权法案》的解读文章,无研究设计与样本。

主要发现

  • 自2017年初起提供者接受质量评估,后续年份评估成本;高质量低成本获奖励,低质量高成本受罚。
  • CMS通过开发中的诊疗 episode 和替代支付模型评估成本;透析替代支付模型已实施,但未涵盖CKD向ESRD过渡。

关键数值与推荐

  • 自2017年初起评估质量,后续年份评估成本;高质量低成本获奖励,低质量高成本受经济惩罚。

临床怎么用

  • 肾脏病提供者应发展成本效益高的护理方式,特别是关注CKD向ESRD过渡期的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In response to rising Medicare costs, Congress passed the Medicare Access and Children's Health Insurance Program Reauthorization Act in 2015. The law fundamentally changes the way that health care providers are reimbursed by implementing a pay for performance system that rewards providers for high-value health care. As of the beginning of 2017, providers will be evaluated on quality and in later years, cost as well. High-quality, cost-efficient providers will receive bonuses in reimbursement, and low-quality, expensive providers will be penalized financially. The Centers for Medicare and Medicaid Services will evaluate provider costs through episodes of care, which are currently in development, and alternative payment models. Although dialysis-specific alternative payment models have already been implemented, current models do not address the transition of patients from CKD to ESRD, a particularly vulnerable time for patients. Nephrology providers have an opportunity to develop cost-efficient ways to care for patients during these transitions. Efforts like these, if successful, will help ensure that Medicare remains solvent in coming years.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Lin E, MaCurdy T, Bhattacharya J, et al. The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology. J Am Soc Nephrol. 2017. PMID: 28754790. doi:10.1681/ASN.2017040407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。